#USA #Philadelphia #Field Medical #FieldForce #VT

Innovative Approach to Treating Ventricular Tachycardia with Field Medical's FieldForce™

Field Medical, Inc. has recently announced promising outcomes from the first-ever Ventricular Catheter Ablation Study (VCAS) utilizing their new FieldForce™ Ablation System. This system leverages a unique pulsed field technology designed to treat ventricular tachycardia (VT) effectively. On October 10, 2025, important findings from this six-month study were published in the respected journal Circulation and presented at the 20th International Symposium on Ventricular Arrhythmias.

Study Overview

The VCAS study is a multicenter feasibility trial aimed at assessing the safety and performance of the FieldForce™ system among patients suffering from VT. This pioneering system employs a proprietary high-voltage waveform that delivers short pulses. This innovative approach is intended to penetrate dense scar tissue while keeping thermal damage to a minimum.

Key Results

The findings from the study are impressive: 82% of patients showed no recurrence of VT or need for further treatment involving implantable cardioverter-defibrillators (ICDs). Moreover, there was a remarkable 98% reduction in the burden of VT episodes. Impressively, only 11.5% of patients experienced primary safety events, with no treatment-related complications reported.

Dr. Vivek Reddy, one of the lead investigators and an electrophysiologist at Mount Sinai, expressed optimism about these results. He remarked, “Although this is an initial feasibility study, the results after six months are very encouraging. An 82% absence of recurrence along with a drastic reduction in arrhythmia frequency represents significant advancements in treating VT, especially considering this is the first evidence showcasing that pulsed field ablation can reach deep scar tissue in the ventricle.”

Dr. Reddy further commented that refining this approach could lead to major breakthroughs in treating arrhythmias associated with scarring.

Regulatory Progress

Following these promising results, Field Medical's FieldForce system has been granted Breakthrough Device Designation by the FDA. This allows for expedited evaluation, assisting its transition toward pivotal trials. Dr. Steven Mickelsen, founder and technology director at Field Medical, noted, “Obtaining initial feasibility data published in Circulation emphasizes the significance of our work. We have always aimed to combine scientific credibility with innovation. These results represent a significant step as we continue to assess pulsed field ablation’s potential to enhance patient outcomes.”

Future Directions

Field Medical is not stopping here. The company is committed to exploring further applications of the FieldForce™ technology beyond VT and anticipates presenting initial feasibility results in treating atrial fibrillation (AF) at a major scientific meeting in early 2026.

About Field Medical®

Founded in 2022, Field Medical is a clinical-stage medical technology company focused on advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. The FieldForce™ ablation system combines a focal catheter design with proprietary FieldBending technology, aiming to ensure safe, efficient, and precise ablations that improve outcomes for patients experiencing ventricular and atrial arrhythmias.

To learn more about the innovations from Field Medical, visit www.fieldmedicalinc.com or follow them on social media. Remember, the FieldForce™ system is an experimental device limited by federal law for research purposes only.